Abstract
No public abstract is available from the verified source records.
Herbert Y Meltzer
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Cognitive impairment in schizophrenia
10.1007/978-3-642-25758-2_2 · 2012
Time for new schizophrenia Rx
10.1126/science.1252603 · 2014
The NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond
10.1016/j.coph.2014.12.004 · 2015
Identifying pathways leading to prefrontal GABA-ergic interneuron dysfunction in schizophrenia
10.1176/appi.ajp.2014.14060750 · 2014
Lower expression of glutamic acid decarboxylase 67 in the prefrontal cortex in schizophrenia: contribution of altered regulation by Zif268
10.1176/appi.ajp.2014.14010004 · 2014
GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder
10.1016/s0893-133x(01)00225-1 · 2001
Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine
10.1073/pnas.89.10.4270 · 1992
A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia
10.1016/j.neuron.2010.02.014 · 2010
F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum
10.1016/j.ejphar.2009.08.019 · 2009
Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism
10.1016/s0006-8993(02)03570-9 · 2002
Clozapine to n-desmethylclozapine plasma concentrations ratio predicts working memory performance in schizophrenia
10.1176/appi.ajp.2015.14050673 · 2015
Attention must be paid: the plasma clozapine/N-desmethylclozapine (NDMC) ratio association with working memory and its relevance to the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS)
10.1176/appi.ajp.2015.15030338 · 2015
Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice
10.1073/pnas.0710373105 · 2008
Neuregulin1 signaling promotes dendritic spine growth through kalirin
10.1111/jnc.12330 · 2013
Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia
10.1017/s1461145713000928 · 2013
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
10.1001/archpsyc.64.6.633 · 2007
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia
10.4088/jcp.09m05793yel · 2011
What have we learned about trial design from NIMH-funded pragmatic trials?
10.1038/npp.2010.115 · 2010
Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality
10.1001/archpsyc.1987.01800220077011 · 1987
Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist
10.1124/jpet.109.156349 · 2010
Procedural learning in schizophrenia: further consideration on the deleterious effect of neuroleptics
2000
Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans
10.1016/j.biopsycho.2006.01.005 · 2006
A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects
10.1016/j.schres.2006.08.021 · 2007
Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine
10.1016/0006-3223(93)90043-d · 1993
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
10.1001/archpsyc.64.10.1115 · 2007
The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis
10.1093/oxfordjournals.schbul.a033374 · 1999
A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia
10.1017/s146114570500516x · 2005
Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis
10.1007/s00228-013-1600-y · 2014
Antipsychotic effects on cognition in schizophrenia: a meta-analysis of randomised controlled trials
10.4321/s0213-61632009000200002 · 2009
Second-generation antipsychotic effect on cognition in patients with schizophrenia—a meta-analysis of randomized clinical trials
10.1111/acps.12374 · 2015
Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride
10.1038/sj.npp.1300626 · 2005
The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats
10.1124/jpet.111.180638 · 2011
Effects of clozapine on cognitive function in schizophrenia
1994
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis
10.1016/j.biopsych.2005.06.022 · 2006
Early-stage Schizophrenia Outcome Study I: neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study
10.1016/j.neulet.2011.08.027 · 2011
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
10.1176/appi.ajp.159.6.1018 · 2002
D(1) receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats
10.1016/j.bbr.2012.09.030 · 2013
Molecular and cellular cognitive studies of the role of synaptic plasticity in memory
10.1002/neu.10169 · 2003
Neurocognitive-genetic and neuroimaging-genetic research paradigms in schizophrenia and bipolar disorder
10.1007/s00702-011-0672-z · 2011
Anatomical specificity in the modulation of activity-regulated genes after acute or chronic lurasidone treatment
10.1016/j.pnpbp.2013.12.008 · 2014
Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?
10.1016/j.bbr.2008.05.016 · doi-reference
Mouse behavioral endophenotypes for schizophrenia
10.1016/j.brainresbull.2010.04.008 · doi-reference
Neurophysiological and computational principles of cortical rhythms in cognition
10.1152/physrev.00035.2008 · doi-reference
Storage, recall, and novelty detection of sequences by the hippocampus: elaborating on the SOCRATIC model to account for normal and aberrant effects of dopamine
10.1002/hipo.1071 · doi-reference
The Neuroplastin adhesion molecules: key regulators of neuronal plasticity and synaptic function
10.1111/jnc.12816 · doi-reference
Synaptotagmin IV: biochemistry, genetics, behavior, and possible links to human psychiatric disease
10.1385/mn:23:2-3:173 · doi-reference
Immature dentate gyrus: an endophenotype of neuropsychiatric disorders
10.1155/2013/318596 · doi-reference
Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor
10.1017/s1461145713001466 · doi-reference
Distributed network actions by nicotine increase the threshold for spike-timing-dependent plasticity in prefrontal cortex
10.1016/j.neuron.2007.03.006 · doi-reference
Functional and dysfunctional synaptic plasticity in prefrontal cortex: roles in psychiatric disorders
10.1016/j.biopsych.2009.08.026 · doi-reference
Serotonergic 5-HT7 receptors and cognition
10.1515/revneuro-2013-0066 · doi-reference
The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia
10.1515/revneuro-2014-0005 · doi-reference
Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions
10.1007/978-3-642-23274-9_8 · doi-reference
Dementia praecox redux: a systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia
10.1177/0269881114564096 · doi-reference
Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat
10.1097/fbp.0b013e32831c3b06 · doi-reference
In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems
10.1016/s0079-6123(08)00909-6 · doi-reference
A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia
10.1016/j.schres.2014.02.015 · doi-reference
Increased grey matter densities in schizophrenia patients with negative symptoms after treatment with quetiapine: a voxel-based morphometry study
10.1097/yic.0b013e32831daf6c · doi-reference
The cognitive genetics of neuropsychiatric disorders
10.1007/7854_2011_188 · doi-reference
Behavioral animal models to assess pro-cognitive treatments for schizophrenia
10.1007/978-3-642-25758-2_3 · doi-reference